Neolabs face impossible odds trying to achieve both research breakthroughs and venture-scale business success simultaneously. The article proposes adopting a pharma-style model where specialized research labs focus purely on scientific breakthroughs while larger frontier labs handle commercialization and scaling, reducing pressure on early-stage AI companies.